Combination of in vivo monitoring and flow cytometry-based immunoprofiling on syngeneic tumor models

05 / 24 / 2019

Syngeneic tumor models were becoming invaluable for preclinical development and evaluation of immuno-based therapies in the presence of a functional immunocompetent system. Explicyte is providing a series of syngeneic mouse models including subcutaneous and orthotopic models, which were fully characterized in terms of their responsiveness to immune checkpoint inhibitors (ICI) and their immune infiltration features using a high throughput-compatible flow cytometry platform.



While the potential of various immunological modulators (e.g. ICI) to provide an anti-tumor immune-driven response can be evaluated through in vivo monitoring, efficacy of many of these modulators is usually underlied by a strong impact on the immune system, which thus needs to be delineated through relevant models and immunological readouts, in order to see whether the modulation of immune subset responses correlates with the impact of therapeutics on tumor growth. Furthermore, depending on their responsiveness degree to immunotherapeutics, tumor models differ in extent and type of immune cell modulation, while the in vivo tumor responses can be similar. Profiling immune cell function permits for building a complete package with in vivo data for a deeper understanding of how a cancer therapy performs.




The data presented here on the sensitivity of four syngeneic tumor models to PD1/PDL1 axis blockade and the way this latter can – differentially – affect immune cell populations over these models, provide a good overview of our comprehensive service offerings combining syngeneic tumor models and flow cytometry analysis to characterize the effects on anti-tumor immunity and decipher mechanism(s) of action of novel immunotherapeutics.


                                     Contact us to test your drug(s)!